Indication

Extensive disease small cell lung cancer

1 clinical trial

1 drug

Clinical trial

Sintilimab Combined With Anlotinib as Second- or Further-line Therapy for Extensive Disease Small Cell Lung Cancer: A Prospective, Single-arm, Phase II Study

Status: Completed, Estimated PCD: 2023-05-01

Drug